In digestive system cancer research, MUC13 was observed to be highly expressed in pancreatic cancer, impacting HER2 receptor tyrosine kinase activity, which initiated NF-κB p65 activation and nuclear translocation, along with IκB phosphorylation, thereby enhancing tumor progression 60. Here, ERBB2 is linked to familial pancreatic carcinoma.